Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rapastinel Monotherapy in MDD
NCT03560518Phase 3Terminated
- Sponsor
- Allergan
- Start
- Jun 2018
- Primary completion
- Jul 2019
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of rapastinel in major depressive disorder (MDD), sponsored by Allergan. Started Jun 2018; status: terminated.
02
Drugs
rapastinel
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03560518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03560518.